South Africa's regulator SAHPRA has registered a long-acting monoclonal antibody from Sanofi to protect infants against respiratory syncytial virus (RSV) [2].
The approval provides a new preventive tool for a virus that frequently leads to severe lower respiratory tract infections in newborns and young children. Reducing infant hospitalizations during peak RSV seasons can alleviate pressure on the South African healthcare system.
Jean-Baptiste Bregeon, the head of vaccines and country lead for Sanofi South Africa, said there is a need for increased public awareness regarding the virus. He said around two in three babies will catch RSV before their first birthday [1].
The monoclonal antibody is designed to provide long-term protection by mimicking the body's natural immune response. This preventive measure targets the virus before it can cause severe illness in the lungs, a critical intervention for the most vulnerable infants.
Bregeon said the registration by SAHPRA marks a significant step in addressing the impact of RSV. The treatment aims to lower the frequency of severe cases that require hospitalization [2].
Public health officials said that RSV is a common cause of bronchiolitis and pneumonia in infants. While many children experience mild symptoms, the risk of severe respiratory distress remains a primary concern for caregivers and clinicians alike.
“Around two in three babies will catch RSV before their first birthday”
The registration of a monoclonal antibody in South Africa represents a shift toward proactive prevention for RSV, which has historically lacked widespread preventive treatments for infants. By targeting the virus before it causes severe illness, this medical intervention could significantly reduce the seasonal surge of pediatric hospital admissions.
